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to evaluate mean annual total health care cost per-capita and mortality. RESULTS:
The annual rate of first ICD implant (per million-persons) increased, from 55 in 2000
to 236 by 2008. The use of ICD in Lombardy was approximately 2 times higher than
in Europe and 3-4 times lower than in US. The replacement rate was around 10 (per
hundred implant-year) with a peak in 2005. The hospitalization for a first ICD
implant cost €23,814 (CI95%, 23,676-23,960) on average. During follow-up, 15.4% of
patients died and the HS bore a mean annual cost of €4,354 (CI95% 4,226-4,485)
per-capita: 17% due to drugs, 12% to outpatient visits and 71% to hospitalizations.
Younger patients reported lower costs in drug treatments and outpatient visits and
a higher expenditure for hospitalizations. CONCLUSIONS: ICD use is growing and
it’s important to assess the efficacy and the burden of this therapy, given the
economic implications and differences in use among countries. Health care admin-
istrative databases are a useful tool, as they provide information about large unse-
lected populations.
PMD83
THE COST IMPACT OF MODIFYING PATTERNS OF SELF-MONITORING OF BLOOD
GLUCOSE IN AN IRISH TYPE 2 DIABETES COHORT
Usher C1, O’Leary A2, Mulhall C2, Barry M3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2National Centre for
Pharmacoeconomics, Dublin 8, Ireland, 3St. James’s Hospital, Dublin, Ireland, Ireland
OBJECTIVES: International best-practice guidelines for self-monitoring of blood
glucose recommend testing for patients on basal insulin be limited to twice daily,
with periodic testing for patients on oral glucose lowering therapies including in-
sulin secretagogues and insulin sensitisers. The aim of this study is to estimate the
potential cost savings if frequency of self-monitoring of blood glucose in patients
with Type 2 diabetes in Ireland is rationalised according to these guidelines.
METHODS:Data were analysed using 1) a national prescription claims database for
2011 (dispensed data), and 2) a survey conducted on 604 Type 2 diabetes patients in
2011 (self-reported data). Patients receiving prescriptions for diabetes were identi-
fied and total ingredient cost and quantity of test strips dispensed were calculated.
Drugs and diagnostic test strips were classified and identified according to the
WHO ATC classification system. Frequency of testing for various treatment strat-
egies was obtained. Analysis was performed in SAS (v9.1) RESULTS: The total in-
gredient cost of test strips was €24.5m (dispensed data) and €118,625.47 (self-re-
ported data) in 2011. The average frequency of testing for patients on oral agents
was 3 times daily (both insulin secretagogues and sensitisers) (dispensed data)
compared to once daily (self-reported data). CONCLUSIONS: Results from this
study indicate cost savings of approximately €10.4m per annum should frequency
of blood glucose monitoring be restricted to patients on insulin containing regi-
mens alone. The results also highlight a difference in frequency of blood glucose
monitoring between dispensed data and self-reported data, indicating the wastage
that currently exists in the system.
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OBJECTIVES: Model cost-effectiveness of home Telemonitoring (TM) or Structured
Telephone Support (STS) strategies versus usual care for adults recently discharged
(within 28 days) after a Heart Failure (HF) exacerbation in Engalnd and Wales.
METHODS: A Markov model evaluated 4 interventions: a) STS Human to Machine,
b) STS Human to Human, and c) TM during office hours d) usual care. Given heter-
ogeneity in the interventions, cost-effectiveness analysis was performed using
bottom up costing scenarios regarding costs of devices, monitoring and medical
care to deal with alerts. Costs and QALYs over a 30 year horizon depend on monthly
probability of death and monthly risks of hospitalisations (HF-related complica-
tions or other causes) computed using a Bayesian network meta-analysis of inter-
vention trials. RESULTS: Base case monthly costs per patient were: £27 for usual
care, £119 for STS HM, £179 for STS HH and £175 for TM during office hours. The
base case found that TM during office hours was the most cost-effective strategy.
Compared with usual care, TM during office hours had an estimated incremental
cost effectiveness ratio (ICER) of £9,552/QALY, whereas STS HH had an ICER of
£63,240/QALY against TM during office hours. STS HM was dominated by usual
care. PSA showed probabliities of cost-effective for TM during office hours cost
effective of 44%, STS HH 36%, STS HM 18% and usual care 2%. Threshold analysis
suggested that the monthly cost of TM during office hours has to be higher than
£390 to have an ICER greater than £20,000/QALY against STS HH. Scenario analyses
performed using higher costs of usual care, higher costs of STS HH and lower costs
of TM during office hours do not substantially change the conclusions.
CONCLUSIONS:Cost-effectiveness analyses suggest TM during office hours was an
optimal strategy in most scenarios, but there is considerable uncertainty in relation
to clear descriptions of the interventions and robust estimation of costs.
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OBJECTIVES: The health care sector in India is growing rapidly while facing in-
creased demands for quality and efficiency of care. We have developed an agent-
based model (ABM) of cardiovascular disease (CVD) for India to inform relevant
health care policy and investment decisions by simulating infrastructure expan-
sion scenarios and estimating associated health care requirements and health and
economic impacts. METHODS: The primary agents in our model are individual
health care facilities, including hospitals and health care centers. Health care fa-
cilities are configured by model users and placed in selected jurisdictions to simu-
late multiple CVD diagnostic and treatment strategies over a time horizon of up to
20 years. A facility description includes basic patient information, the catchment
population served by the facility, the diagnostic capacity of that facility (e.g., how
many ECG tests the facility can provide), and the diagnostic strategies used by that
facility to diagnose CVD. Multiple sets of patient-strategy combinations can be
defined for each facility allowing for inter-facility and intra-facility comparisons.
Using this information, each facility in the CVD model calculates a total patient
population, segments the patient population into individual patient groups, and
runs these groups through specified diagnostic strategies. Our CVD ABM was de-
veloped using the Repast Simphony ABM environment. RESULTS: The results of
running each patient group through the specified strategies are recorded and used
to calculate multiple health and economic summary metrics. The metrics include
diagnostic outcomes, costs, quality-adjusted life years, capacity metrics, and a
customized composite score. The results of an example scenario will be reported.
CONCLUSIONS: CVD ABM has potential to inform complex health care infrastruc-
ture investment decisions that could improve access to CVD care and positively
affect health and economic outcomes, while increasing operational efficiency of
health care delivery in India.
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OBJECTIVES: In Japan, cancer screening is not covered by health insurance, but is
provided and paid for by local governments. In clinical practice, asymptomatic
subjects have undergone upper gastrointestinal endoscopy as cancer screening
that has been charged to health insurance. In order to file a claim for health insur-
ance, the actual name of the disease must be reported even for an asymptomatic
person. The number of upper gastrointestinal endoscopic examinations for asymp-
tomatic persons in clinical practices was estimated based on the national health
insurance data and the national patients’ survey. METHODS: There were 501,002
endoscopic examinations and 178,200 persons with gastric diseases in 2008. The
appropriate numbers of endoscopic examinations were calculated based on the
following models. At admission, an endoscopic examination was performed once
for each patient. For outpatient cases at the first visit, an endoscopic examination
was performed once for gastric and esophageal cancer patients and 0.5 times for
patients with another upper gastrointestinal disease. For outpatient follow-up,
patents were examined once a year if they had a gastric cancer or an esophageal
cancer and 0.5 times a year if they had another upper gastrointestinal disease. A
sensitivity analysis of the number of endoscopic examination of outpatients with
another upper gastrointestinal disease was performed by changing the number of
examinations from 0.1 to 0.8 times for outpatients both at the first visit and at
follow-up. The difference between the estimated and observed numbers was de-
fined as representing the number of inappropriate endoscopic examination per-
formed for asymptomatic patients. RESULTS: Using the initial assumptions,
asymptomatic patients accounted for 30.8% of all cases undergoing upper endos-
copy. On sensitivity analysis, this ranged from 2.2% to 69.0%. CONCLUSIONS: The
results suggest that a substantial number of upper gastrointestinal endoscopies are
performed for asymptomatic patients in clinical practice, and this cannot be ig-
nored.
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OBJECTIVES: The data from clinical trials show, that in patients with advanced
non-small-cell lung-cancer and with activating EGFR-mutations first-line use of
tyrosine kinase inhibitors (TKI) may be of advantage compared to standard doublet
chemotherapy. However, testing of all newly diagnosed patients with advanced
NSCLC has been considered as a financial burden in daily clinical routine. The rate
of EGFR-testing in daily practice was analyzed by institution type, histology, indi-
vidual patient characteristics and by federal state. The EGFR-test processing was
analyzed with respect to sampling, quality of samples, referral to the certified
pathologists, reimbursement and coverage of costs. METHODS: The online survey
was performed in a representative sample of decision making physicians in 102
centres (21 university hospitals, 44 non-university hospitals, 32 office-based oncol-
ogists, 5 lung clinics) treating patients with advanced NSCLC in the 3rd quarter of
2011. The impact of relevant factors (turn-around time, regional density of hospi-
tals or specialist physicians, the type of test-initiating institution) on the likelihood
of testing was assessed by using a two-sided Chi-square test RESULTS: Only a
minority of patients with NSCLC IIIb/IV (40%) had access to EGFR-testing and to the
respective treatment in case of a mutation in Q3 2011. Reasons may include the
long waiting-time for test results (mean 9.2 d, range 5-14 d), the inadequate reim-
bursement of testing, esp. in lung clinics, and patient selection according to indi-
vidual characteristics by the physician in order to reduce the test rates and the
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